8th Annual Generic Drugs Summit

Online registration is open!

Thanks to all of our event sponsors, for their contributions to this event!

Thanks to all of our event Media Partners, for their contributions to this event!

Have a question about this event?
Customer Service representatives are available to help from 8 AM - 6 PM EST
Call 888-670-8200

Need Technical Assistance With this Website?
Send an email to IIR's Web Department

Home»Events»8th Annual Generic Drugs...Event Overview»Agenda Day One

8th Annual Generic Drugs Summit

when and where

September 17 - 19, 2007 | The Fairmont, Washington , DC

doc title

Agenda Day One

MAIN CONFERENCE DAY ONE: TUESDAY, SEPTEMBER 18, 2007

7:00	Registration and Morning Coffee
8:00	Chairperson's Opening Remarks Shashank Upadhye, Esq., Vice President - Head of Intellectual Property, Sandoz U.S., SANDOZ, INC.
CONGRESSIONAL ADDRESS
8:15	Update on Hatch-Waxman Reform The Honorable Henry A. Waxman, MEMBER OF CONGRESS, UNITED STATES, CALIFORNIA DISTRICT 30
KEYNOTE ADDRESS
9:15	Regulatory Issues Impacting Generic Drugs Scott Gottlieb, MD, Resident Fellow, AMERICAN ENTERPRISE INSTITUTE FOR PUBLIC POLICY RESEARCH; Former Deputy Commissioner for Medical and Scientific Affairs, FDA
9:45	Morning Refreshment and Networking Break
VIEW FROM THE HILL
10:15	The Future of Generic Drugs: What's Happening on Capitol Hill? Panelists: Scott Gottlieb, MD, Resident Fellow, AMERICAN ENTERPRISE INSTITUTE FOR PUBLIC POLICY RESEARCH; Former Deputy Commissioner for Medical and Scientific Affairs, FDA Suzanne M. Sensabaugh, Vice President, Biopharmaceutical Development, MDS PHARMA SERVICES Steven E. Irizarry, Vice President of Government Affairs, ML STRATEGIES, LLC; Former Senior Health Counsel to the Senate Special Committee on Aging and the Senate HELP Committee Amy Muhlberg, PhD, Professional Staff Member, Committee on Health, Education, Labor, and Pensions, OFFICE OF US SENATOR MIKE ENZI (invited) David Dorsey, Legislative Assistant, Office of US Senator, EDWARD KENNEDY (invited)
FTC ADDRESS
11:00	Federal Trade Commission Actions Involving Generic Drugs Markus H. Meier, Assistant Director, Healthcare Division, FEDERAL TRADE COMMISSION, BUREAU OF COMPETITION INDUSTRY KEYNOTE
11:45	Building Upon A Global Vision and Aggressive Growth Strategy in Today's Competitive Marketplace Douglas S. Boothe, Executive Vice President and Chief Operating Officer, Actavis US, ACTAVIS GROUP HF
12:30	Luncheon for Delegates and Speakers

Concurrent Tracks Begin

	Track A: Intellectual Property & Legal Issues	Track B: Business Trends & Strategy
1:45	To Go Ahead or Not: How to Make the Most of Due Diligence Beverly W. Lubit, Esq., PhD, Partner, Intellectual Property/Information Technology Practice Group, WOLF, BLOCK, SCHORR & SOLIS-COHEN LLP	Brand-Generic Settlements: Deal or No Deal? Meredyth Smith Andrus, Attorney, Health Care Services and Products Division, FEDERAL TRADE COMMISSION, BUREAU OF COMPETITION Steven J. Lee, PhD, Partner, KENYON & KENYON David Balto, ATTORNEY AT LAW
2:30	Trends in New Pharmaceutical Patent Claim Strategies Shashank Upadhye, Esq., Vice President - Head of Intellectual Property, Sandoz U.S., SANDOZ, INC.	2007 US Strategic Management Review: Trends, Issues, Outlook Douglas M. Long, Vice President, Industry Relations, IMS HEALTH, INC
3:15	Refreshment and Networking Break